Stockscreener 앱 받기
31.12
3.11%
-1.00
전일 마감가:
$32.12
열려 있는:
$32.04
하루 거래량:
5.68M
Relative Volume:
0.53
시가총액:
$12.42B
수익:
$5.06B
순이익/손실:
$-2.22B
주가수익비율:
-5.3471
EPS:
-5.82
순현금흐름:
$-3.96B
1주 성능:
-4.72%
1개월 성능:
+0.10%
6개월 성능:
-52.67%
1년 성능:
-70.80%
1일 변동 폭
$31.02
$32.50
1주일 범위
$31.02
$34.87
52주 변동 폭
$29.25
$170.47
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
MRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
31.12 | 12.42B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Teacher Retirement System of Texas Purchases 12,651 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Has $25.79 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
KLP Kapitalforvaltning AS Invests $4.44 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Vanguard Group Inc. Boosts Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Stake Lowered by Corient Private Wealth LLC - MarketBeat
Royal London Asset Management Ltd. Sells 178,991 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Is Moderna Stock A Sell With RFK Jr. Reportedly Eyeing Funds? - Investor's Business Daily
Jim Cramer: Moderna (MRNA) Blew It – But Their Cash Pile Could Save Them! - Insider Monkey
Moderna's Options Frenzy: What You Need to Know - Benzinga
Moderna, Inc. (MRNA): Among Stocks To Trade Without Tariffs And Interest Rate Fears - Insider Monkey
Motley Fool Wealth Management LLC Sells 31,583 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Trump administration at ‘war’ with mRNA technology: scientists alarmed vaccine skeptics could kill research - Inkl
As Vaccine Skepticism Mounts, Moderna’s Business Grows More Precarious - Barron's
Moderna chief brand officer Kate Cronin exits pharma giant - MM+M Online
Moderna, Novavax Shares Are Sliding Wednesday: What's Going On?Moderna (NASDAQ:MRNA) - Benzinga
Moderna, Novavax, and Pfizer shares fall amid U.S. vaccine fund cuts - Investing.com
Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of "Hold" by Analysts - MarketBeat
JPMorgan Chase & Co. Lowers Moderna (NASDAQ:MRNA) Price Target to $33.00 - MarketBeat
Northwest & Ethical Investments L.P. Grows Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Is Moderna, Inc. (MRNA) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Raymond James Financial Inc. Purchases New Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars? - Crowell & Moring LLP
Moderna, Inc. (MRNA): Among Stocks with Potential to Explode in 2025 - Insider Monkey
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks - Yahoo Finance
Avantax Advisory Services Inc. Invests $483,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Privium Fund Management B.V. Increases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
mRNA Patent Wars Update: The Plot Thickens with Key Rulings Expected in 2025 - IPWatchdog.com
Moderna price target lowered to $33 from $40 at JPMorgan - Yahoo Finance
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - The Motley Fool
Wealthfront Advisers LLC Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
JPMorgan Cuts Price Target on Moderna to $33 From $40, Maintains Underweight Rating - Marketscreener.com
Proficio Capital Partners LLC Raises Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Swiss National Bank - MarketBeat
Skandinaviska Enskilda Banken AB publ Decreases Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
U.S. to spend $100M to develop bird flu vaccines, drugs (MRNA) (MRNA:NASDAQ) - Seeking Alpha
Moderna's Options: A Look at What the Big Money is Thinking - Benzinga
4 Things You Need to Know if You Buy Moderna Stock Today - Nasdaq
Intact Investment Management Inc. Invests $420,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Victory Capital Management Inc. Sells 168,512 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna. Why Anti-Covid19 Juggernaut Goes 'The Bloodmachine' for NASDAQ:MRNA by PandorraResearch - TradingView
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
모더나 주식 (MRNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SAGAN PAUL | Director |
Mar 03 '25 |
Buy |
31.76 |
31,620 |
1,004,251 |
312,027 |
| Klinger Shannon Thyme | Chief Legal Officer |
Dec 09 '24 |
Sale |
44.68 |
529 |
23,637 |
20,446 |
0.39%
0.34%
자본화:
|
볼륨(24시간):